tiprankstipranks
Galecto (GLTO)
NASDAQ:GLTO

Galecto Stock Analysis & Ratings

GLTO Stock Chart & Stats

Day’s Range$1.36 - $1.4
52-Week Range$1.36 - $16.41
Previous Close$1.39
Volume23.07K
Average Volume (3M)72.61K
Market Cap$35.37M
P/E Ratio-0.6
Beta1.23
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-2.19


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

GLTO FAQ

What was Galecto’s price range in the past 12 months?
Galecto lowest stock price was $1.36 and its highest was $16.41 in the past 12 months.
    What is Galecto’s market cap?
    Galecto’s market cap is $35.37M.
      What is Galecto’s price target?
      The average price target for Galecto is $16.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $16.00 ,the lowest forecast is $16.00. The average price target represents 1042.86% Increase from the current price of $1.4.
        What do analysts say about Galecto?
        Galecto’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Galecto’s upcoming earnings report date?
          Galecto’s upcoming earnings report date is Aug 04, 2022 which is in 78 days.
            How were Galecto’s earnings last quarter?
            Galecto released its earnings results on Apr 29, 2022. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.67.
              Is Galecto overvalued?
              According to Wall Street analysts Galecto’s price is currently Undervalued.
                Does Galecto pay dividends?
                Galecto does not currently pay dividends.
                What is Galecto’s EPS estimate?
                Galecto’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Galecto have?
                Galecto has 25,260,000 shares outstanding.
                  What happened to Galecto’s price movement after its last earnings report?
                  Galecto reported an EPS of -$0.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.599%.
                    Which hedge fund is a major shareholder of Galecto?
                    Among the largest hedge funds holding Galecto’s share is Maverick Capital ltd. It holds Galecto’s shares valued at N/A.

                      ---

                      Galecto Stock Analysis

                      The Galecto stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Galecto

                      Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis & impact a broad range of fibrotic & related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

                      ---
                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis